Cargando…
Vascular Niche Facilitates Acquired Drug Resistance to c-Met Inhibitor in Originally Sensitive Osteosarcoma Cells
SIMPLE SUMMARY: Osteosarcoma (OS) is a common malignant bone tumor in adolescents whose survival rates have not improved over the past few decades. At present, there is a lack of effective molecule-targeted therapy. Abnormal activation of c-Met is often detected in patients with OS, and c-Met inhibi...
Autores principales: | Tang, Weifeng, Zhang, Yu, Zhang, Haixia, Zhang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776923/ https://www.ncbi.nlm.nih.gov/pubmed/36551686 http://dx.doi.org/10.3390/cancers14246201 |
Ejemplares similares
-
Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021) -
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020) -
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019) -
A c-Met Inhibitor Suppresses Osteosarcoma Progression via the ERK1/2 Pathway in Human Osteosarcoma Cells
por: Chen, Weijie, et al.
Publicado: (2021) -
MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)